Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gelatin methacryloyl-mediated integration of lithium cobalt oxide with carbon nanotubes for a conductive composite.

Nanoscale·2026

Same author

<i>Chrysanthemum coronarium</i> suppresses ferroptosis-driven vascular hyperplasia following carotid artery ligation in mice.

Food science and biotechnology·2026

Same author

Computational carrier dynamics across heterojunction interface between hole injection and transport layers in quantum-dot light-emitting diodes.

Scientific reports·2026

Same author

Long-term effects of preterm birth on cortical folding trajectories in early childhood.

Brain communications·2026

Same author

A comparative analysis of pig-to-rhesus corneal xenotransplantation with various immunosuppressive regimens.

Korean journal of ophthalmology : KJO·2026

Same author

Effect of water activity and light exposure on the stability of bioactive compounds in matcha (Camellia sinensis) powder during storage periods.

Food chemistry·2026

Search research articles

Related Experiment Video

Updated: May 13, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection.

Myung Ae Kim¹, Soon Il Choi¹, Jong Min Kim¹

¹Retina Center, Nune Eye Hospital, Seoul, Korea.

Korean Journal of Ophthalmology : KJO

|April 16, 2025

Summary

Brolucizumab reinjection after intraocular inflammation (IOI) shows varied outcomes. While some patients experience no recurrence, a significant portion may have recurrent IOI, necessitating careful consideration for continued brolucizumab use.

Keywords:

Brolucizumab Intravitreal injections Macular degeneration Uveitis

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

Related Experiment Videos

Last Updated: May 13, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach

Published on: December 7, 2016

Area of Science:

Ophthalmology
Retinal diseases
Pharmacology

Background:

Brolucizumab is a novel anti-VEGF agent used for retinal diseases.
Intraocular inflammation (IOI) is a known complication associated with brolucizumab treatment.
Understanding the outcomes of continuing brolucizumab after IOI is crucial for patient management.

Purpose of the Study:

To investigate the incidence and outcomes of intraocular inflammation (IOI) following brolucizumab injections.
To evaluate the safety and efficacy of brolucizumab reinjection in patients who have previously developed IOI.

Main Methods:

Retrospective analysis of patients receiving brolucizumab from April 2021 to January 2024.
Patients who developed IOI were categorized based on reinjection, discontinuation, and recurrence of IOI.
Incidence rates of IOI and occlusive retinal vasculitis were calculated.

Main Results:

The incidence of IOI was 8.1% (38/472 eyes) and 2.0% (50/2468 injections).
Recurrence of IOI occurred in 23.7% (9/38 eyes), with three patients continuing brolucizumab despite recurrence.
Fifteen cases developed IOI within one week of injection, with an average time to first IOI of 18.60 days.

Conclusions:

Brolucizumab-associated IOI has a notable incidence, with a significant recurrence rate.
Careful monitoring and individualized treatment decisions are essential for patients experiencing IOI with brolucizumab.
Further research is needed to optimize the use of brolucizumab in patients with a history of IOI.